Table 1.
Patientand treatment characteristics
| Characteristic | n=338 | |
| Age at first ASCT, years | ||
| median (range) (IQR) | 37.3 (18.1–69.6) (27.6–49.7) | |
| Histology | n | % |
| Leiomyosarcoma | 66 | 19.5 |
| Synovial sarcoma | 52 | 15.4 |
| Angiosarcoma* | 40 | 11.8 |
| Liposarcoma | 34 | 10.1 |
| Desmoplastic small round cell tumour | 10 | 3 |
| other STS† | 136 | 40.2 |
| Tumour grading | n | % |
| Grade 1 | 4 | 3.8 |
| Grade 2 | 18 | 17.3 |
| Grade 3 | 82 | 78.8 |
| missing | 234 | – |
| Remission status before ASCT | n | % |
| Complete response/no evidence of disease | 55 | 20.1 |
| Partial response | 107 | 39.1 |
| Stable disease | 28 | 10.2 |
| Progressive disease | 84 | 30.7 |
| Missing | 64 | – |
| Year of first ASCT | n | % |
| 1996–2000 | 152 | 45.0 |
| 2001–2005 | 111 | 32.8 |
| 2006–2016 | 75 | 22.2 |
| Preparative regimen | n | % |
| PEI/CEI | 71 | 42.5 |
| Other platinum based | 31 | 18.6 |
| Melphalan based | 42 | 25.1 |
| Other | 23 | 13.8 |
| missing | 171 | – |
| Remission status after last ASCT | n | % |
| Complete response/no evidence of disease | 94 | 58.4 |
| Partial response | 19 | 11.8 |
| Stable disease | 22 | 13.7 |
| Progressive disease | 26 | 16.1 |
| missing | 177 | – |
*Including haemangiosarcoma and lymphangiosarcoma.
†Including: fibrosarcoma: n=8, malignant fibrous histiocytoma: n=3, sarcoma NOS: n=2, malignant peripheral nerve sheath tumour: n=2, fibromyxoid sarcoma: n=1, sarcoma not further subclassified: n=120.
ASCT, autologous stem cell transplantation; CEI, Carboplatinum, Etoposide, Ifosfamide; NOS, not otherwise specified; PEI, Cisplatinum, Etoposide, Ifosfamide; STS, soft-tissue sarcoma.